EPA Transcriptomic Assessment Product (ETAP) for Perfluoro-3-Methoxypropanoic Acid

The EPA Transcriptomic Assessment Product (ETAP) is a human health assessment that utilizes a standardized short-term in vivo study design and data analysis procedures to develop transcriptomic-based reference values for data poor chemicals. The reference value represents the daily dose of the chemical that would likely be without appreciable risk to human health over a lifetime. This dataset corresponds to the transcriptomic studies on perfluoro-3-methoxypropanoic acid (DTXSID70191136). More information about ETAP is available at: https://www.epa.gov/etap Overall design: A 5-day repeated dose exposure study for perfluoro-3-methoxypropanoic acid was performed in both male and female Sprague Dawley rats separated into 9 dose groups plus vehicle control animals. The vehicle was deionized water and route of exposure was oral gavage (5 ml/kg). Tissues were removed and preserved 24 hours following the last dose. Transcriptomic measurements were performed using targeted RNA sequencing in kidney, liver, adrenal gland, brain, heart, lung, ovary (females), spleen, testis (males), thyroid, thymus, and uterus (females). More details on the study design are available at: https://doi.org/10.23645/epacomptox.25352962

EPA转录组学评估产品（EPA Transcriptomic Assessment Product, ETAP）是一类人体健康评估工具，采用标准化的短期体内研究设计与数据分析流程，为数据匮乏的化学品开发基于转录组学的参考值。该参考值指化学品在终身每日暴露下，大概率不会对人体健康造成明显风险的摄入剂量。本数据集对应全氟-3-甲氧基丙酸（perfluoro-3-methoxypropanoic acid, DTXSID70191136）的转录组学研究。有关ETAP的更多信息可访问：https://www.epa.gov/etap

整体实验设计：针对全氟-3-甲氧基丙酸，研究设置9个剂量组与赋形剂对照组，对雄性与雌性Sprague Dawley大鼠开展为期5天的重复给药暴露研究。赋形剂为去离子水，给药途径为经口灌胃（给药体积为5 ml/kg）。末次给药24小时后采集组织并保存。研究采用靶向RNA测序技术，对肾脏、肝脏、肾上腺、脑、心脏、肺、卵巢（雌性）、脾脏、睾丸（雄性）、甲状腺、胸腺以及子宫（雌性）开展转录组学检测。有关该研究设计的更多细节可访问：https://doi.org/10.23645/epacomptox.25352962